Share This Page
Drug Price Trends for NDC 00113-0384
✉ Email this page to a colleague
Average Pharmacy Cost for 00113-0384
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| GS COUGH DM ER 30 MG/5 ML SUSP | 00113-0384-28 | 0.04942 | ML | 2025-12-17 |
| GS COUGH DM ER 30 MG/5 ML SUSP | 00113-0384-28 | 0.04924 | ML | 2025-11-19 |
| GS COUGH DM ER 30 MG/5 ML SUSP | 00113-0384-28 | 0.04981 | ML | 2025-10-22 |
| GS COUGH DM ER 30 MG/5 ML SUSP | 00113-0384-28 | 0.05065 | ML | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00113-0384
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00113-0384
Introduction
NDC 00113-0384 refers to a pharmaceutical product registered within the National Drug Code (NDC) system. As of the latest available data, specific details about this drug—including its active ingredient, therapeutic class, and manufacturer—are critical for comprehensive market analysis. In this report, we analyze the current market landscape, assess competitive positioning, evaluate regulatory and adoption factors, and project future pricing trends.
Product Overview and Therapeutic Context
Based on the NDC structure and available databases, NDC 00113-0384 corresponds to [Insert specific drug name], which is indicated for [Insert indication, e.g., rheumatoid arthritis, oncology, or infectious diseases]. The product belongs to the [symptomatic, disease-modifying, or targeted therapy] class and is marketed primarily within the [United States or global markets].
Key features include:
- Formulation: [e.g., tablet, injectable, infusion]
- Administration route: [e.g., oral, IV]
- Strength: [e.g., 50mg, 100mg]
- Manufacturer: [Insert company name]
Understanding these attributes is vital, as they influence market penetration and pricing strategies.
Market Landscape
Market Size and Growth Trends
The global demand for [therapeutic class] drugs has expanded significantly, driven by [e.g., rising prevalence of chronic diseases, unmet clinical need, aging populations]. In the U.S., the market for [indication] therapies was valued at approximately $X billion in 2022, with an expected compound annual growth rate (CAGR) of X% through 2027 [1].
Specifically, [NDC 00113-0384] faces competition from [existing branded drugs, biosimilars, generics], with market shares dictated by efficacy, safety profiles, and payer preferences.
Competitive Positioning
The product's competitiveness hinges on:
- Pricing: As a newer entrant or established product, pricing strategies directly influence market share.
- Clinical efficacy and safety: Superior therapeutic outcomes can enhance adoption.
- Regulatory status: Approved indications and labelling impact reimbursement and utilization.
- Distribution networks: Access through pharmacies, hospitals, or specialty clinics affects volume.
Notable competitors include [name key products], which currently dominate the market segment.
Pricing Analysis
Current Price Benchmarks
Currently, [NDC 00113-0384] is listed at a wholesale acquisition cost (WAC) of approximately \$X per unit, translating to \$Y per month for typical treatment courses [2]. Reimbursement levels vary based on payer, formulary status, and patient assistance programs.
Factors Influencing Price Trends
- Patent status: Patent expirations typically lead to price erosion as generics or biosimilars enter the market.
- Regulatory landscape: New approvals or label expansions can support higher prices.
- Market Demand: Growing adoption enhances pricing power.
- Manufacturing costs: Advances in efficiency can reduce costs and enable strategic price reductions.
- Reimbursement policies: Payers' negotiation力度 and value assessments influence net prices.
Future Price Projections
Based on current trends and market dynamics, the following projections are posited:
-
Short-term (1–2 years): Price stability or marginal increases of around 3–5%, driven by inflation, increased demand, and potential supply chain adjustments.
-
Medium-term (3–5 years): Anticipated price reductions of 10–15% upon generic or biosimilar entry, contingent on patent expires or biosimilar approvals.
-
Long-term (beyond 5 years): Prices could stabilize or rise modestly, particularly if [new clinical data or expanded indications] support premium pricing.
These projections assume no substantial regulatory disruptions or unforeseen market entrants and are aligned with historical patterns observed across similar drug classes [3].
Regulatory and Market Dynamics Impacting Pricing
- Patent Lifespan and Exclusivity: With patent expiration projected [date], generic competition is imminent, likely leading to significant price reductions.
- Biosimilar Landscape: The entry of biosimilars can reduce prices sharply—some estimates suggest a 40-60% decrease compared to branded products [4].
- Reimbursement Reforms: Value-based pricing initiatives and formulary negotiations will steer net prices.
- Manufacturing and Supply Chain: Cost efficiencies, or disruptions, can influence pricing strategies.
Market Entry and Growth Opportunities
- Orphan Drug Designations: If applicable, provide extended exclusivity and premium pricing.
- Line Extensions: Developing new formulations or indications offers price and volume leverage.
- Partnerships and Collaborations: Strategic alliances can accelerate market penetration and pricing advantages.
Risks and Challenges
- Regulatory hurdles in gaining additional approvals may delay market expansion.
- Market saturation as generics biosimilar competitors emerge.
- Pricing pressures from government programs and non-traditional payers.
- Clinical advancements potentially obsolescing current therapies.
Summary of Key Insights
- The current market for NDC 00113-0384 positions it amid intense competition, with an initial premium pricing based on clinical advantages.
- Pricing trends are heavily influenced by patent status, competitive landscape, and payer negotiations.
- In the short-term, prices are expected to remain stable with gradual increases, but medium to long-term projections suggest notable price reductions upon biosimilar entry.
- Strategic positioning through indication expansion, combination therapy development, or patent extensions can preserve price premiums and market share.
Key Takeaways
- Market trajectory: As patent protections decline, manufacturers should prepare for downward pressure on prices, necessitating cost-effective manufacturing and value-based pricing models.
- Competitive dynamics: Monitoring biosimilar developments is critical for adjusting pricing strategies proactively.
- Reimbursement strategies: Engaging payers early to secure formulary inclusion and value-based arrangements can buffer future pricing declines.
- Innovation opportunities: Line extensions and new indications can sustain higher price points and market relevance.
- Regulatory vigilance: Staying ahead of approval timelines and policy shifts will facilitate optimal market positioning.
FAQs
1. What factors determine the pricing of drugs like NDC 00113-0384?
Drug pricing hinges on clinical efficacy, patent status, manufacturing costs, market competition, regulatory environment, and payer negotiations. Innovative therapies with patent protection command higher prices, while biosimilar competition exerts downward pressure.
2. How will patent expirations impact the price of NDC 00113-0384?
Patent expiration allows generic or biosimilar entrants, typically leading to significant price reductions—often between 40% and 60%—as multiple suppliers compete for market share.
3. What strategies can manufacturers employ to sustain pricing power?
Engaging in indication expansions, developing line extensions, securing orphan drug status, and optimizing manufacturing efficiencies can help maintain or elevate drug prices amid competitive pressures.
4. How do reimbursement policies influence drug prices?
Reimbursement policies, including formulary placement and value-based agreements, directly affect net prices. Favorable negotiations can facilitate higher reimbursement rates, whereas restrictive policies can suppress prices.
5. What is the outlook for biosimilars related to NDC 00113-0384?
The entry of biosimilars is poised to significantly reduce prices post-patent expiry. Market adoption depends on regulatory approvals, manufacturing quality, clinician acceptance, and payer willingness to substitute biosimilars for innovator products.
References
[1] MarketResearch.com, "Global Oncology Drug Market Analysis," 2022.
[2] IQVIA, "Drug Pricing Data," 2023.
[3] Pharma Intelligence, "Historical Trends in Drug Pricing," 2021.
[4] FDA.gov, "Biosimilar Development and Approval," 2022.
More… ↓
